| NSI-189 Basic information | |
| Product Name: | NSI-189 |
| Synonyms: | (4-BENZYLPIPERAZIN-1-YL)-[2-(3-METHYLBUTYLAMINO)PYRIDIN-3-YL]METHANONE;(4-BENZYLPIPERAZIN-1-YL)(2-(ISOPENTYLAMINO)PYRIDIN-3-YL)METHANONE;[2-[(3-Methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]methanone;[2-[(3-Methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]methanoneNSI189;NSI-189[2-[(3-Methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]methanone;NSI-189,>=98%;(4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl] |
| CAS: | 1270138-40-3 |
| MF: | C22H30N4O |
| MW: | 366.5 |
| Product Categories: | Health food additives; Small molecule inhibitors, natural products; Compound; Inhibitors; API |
| Mol File: | 1270138-40-3.mol |
| Introduction | NSI-189 is an experimental, novel potential antidepressant that is under investigation byNeuralstem, Inc. for the treatment for major depressive disorder (MDD), as well as for cognitive impairment and neurodegeneration. Research into NSI-189 has been funded by theDefense Advanced Research Projects Agency (DARPA) and the National Institutes of Health(NIH).The mechanism of action of NSI-189 appears to be activation of neurogenesis in thehippocampus and possible enlargement of this structure, but how the drug mediates these effects is unknown and binding studies have so far failed to identify any certain molecular targets for the drug. As stated by Neuralstem, NSI-189 is a “new chemical entity with [a] novel mechanism of action, molecular target yet unknown, but not mediated by SSRI or SNRIor by BDNF release or via any known GPCRs, kinases, or channels.” The drug was discovered via high-throughput screening of a library of 10,269 compounds for neurogenic effects in vitro. |
| NSI-189 Chemical Properties | |
| Boiling point | 534.7±50.0 °C(Predicted) |
| density | 1.134±0.06 g/cm3(Predicted) |
| pKa | 6.18±0.10(Predicted) |
